专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100235932A1 ANIMAL MODELS CARRYING TUMORS EXPRESSING HUMAN LIVER CANCER-SPECIFIC ANTIGEN AND METHOD FOR ANALYZING PREVENTION AND TREATMENT EFFICACY OF DENDRITIC CELLS-DERIVED IMMUNOTHERAPEUTICS USING THE ABOVE 审中-公开
标题翻译：携带肿瘤的动物模型表达人肝癌特异性抗原和分析预防和治疗使用上述细胞衍生的免疫球蛋白的效果的方法
公开(公告)号：US20100235932A1
公开(公告)日：2010-09-16
申请号：US12451508
申请日：2008-03-13
申请人： Yong-Soo Bae , Hyun-Soo Lee , Mi-Kyung Min , Cheol-Woong Jeong , Kyu-Ho Kang
发明人： Yong-Soo Bae , Hyun-Soo Lee , Mi-Kyung Min , Cheol-Woong Jeong , Kyu-Ho Kang
IPC分类号： A01K67/00 , C12N5/071
CPC分类号： G01N33/57438 , A61K35/12 , A61K39/0011 , A61K2039/5154 , A61K2039/6075 , C07K14/4748 , C12N2799/027
摘要： The present invention relates to a method for analyzing the prevention and treatment efficacy of a dendritic cell-derived immunotherapeutic for liver cancer using an animal model carrying tumors expressing a human liver cancer-specific antigen, which comprises the steps of: (a) (a1) administering to a normal animal other than human dendritic cells to be analyzed, or (a1) administering to a normal animal other than human a cancer cell line expressing the human liver cancer-specific antigen to induce cancer in the normal animal; (b) (b1) administering to the animal the cancer cell line expressing the human liver cancer-specific antigen to induce cancer in the animal when the step (a1) is performed in the step (a), or (b1) administering to the animal with cancer dendritic cells to be analyzed when the step (a1) is performed in the step (a); and (c) determining the prevention and treatment efficacy of the dendritic cells as immunotherapeutics for liver cancer by measuring the formation or growth of cancer cells originated from the cancer cell line in the animal.
摘要翻译：本发明涉及使用携带表达人肝癌特异性抗原的肿瘤的动物模型分析来自树突状细胞的免疫治疗用于肝癌的预防和治疗功效的方法，其包括以下步骤：（a）（a1））给予除了待分析的人树突状细胞以外的正常动物，或（a1）向正常动物中的表达人肝癌特异性抗原的癌细胞系的人以外的正常动物施用癌细胞系，（b）（b1）在步骤（a）中进行步骤（a1）时，（b1）向动物施用表达人肝癌特异性抗原的癌细胞系以在动物中诱导癌症，或（b1）当在步骤（a）中进行步骤（a1）时，分析具有癌症树突状细胞的动物; 和（c）通过测量来源于动物的癌细胞系的癌细胞的形成或生长来确定树突状细胞作为肝癌的免疫治疗剂的预防和治疗功效。

2. 发明申请

US20090029387A1 METHOD FOR EFFECTIVELY MEASURING THE ACTIVITY OF CYTOTOXIC T LYMPHOCYTES IN HUMAN AND OUT-BRED ANIMALS 审中-公开
标题翻译：用于有效测量人体和野生动物中细胞毒性T淋巴细胞活性的方法
公开(公告)号：US20090029387A1
公开(公告)日：2009-01-29
申请号：US11915738
申请日：2006-05-25
申请人： Sang Won Jung , Yong Soo Bae , Choon Ju Jeon
发明人： Sang Won Jung , Yong Soo Bae , Choon Ju Jeon
IPC分类号： G01N33/566
CPC分类号： G01N33/5091 , C07K7/06
摘要： A method for measuring the activity of cytotoxic T lymphocytes (CTLs) includes preparing peripheral blood mononuclear cells (PBMCs) from blood of an animal; preparing mature dendritic cells by isolating monocytes from the PBMCs, differentiating the monocytes into dendritic cells for presenting an antigen molecule and pulsing dendritic cells with the antigen molecule to obtain the mature dendritic cells; preparing the CTLs as an effector cell by stimulating the PBMCs with the mature dendritic cells to activate and amplify the CTLs; preparing target cells by pulsing the PBMCs, monocytes or B cells with a cytoplasmic transduction peptide (CTP)-antigen complex generated by linking the antigen molecule of step (b) to the CTP; treating the target cells with the effector cells; and analyzing the lysis of the target cells. In addition, a kit for measuring the activity of cytotoxic T lymphocytes is provided.
摘要翻译：用于测量细胞毒性T淋巴细胞（CTL）的活性的方法包括从动物的血液制备外周血单核细胞（PBMC）; 通过从PBMC分离单核细胞来制备成熟树突状细胞，将单核细胞分化成树突状细胞以呈递抗原分子并用抗原分子脉冲树突状细胞以获得成熟的树突状细胞; 通过用成熟树突状细胞刺激PBMC来激活和扩增CTL来制备CTL作为效应细胞; 通过将步骤（b）的抗原分子与CTP连接而产生的细胞质转导肽（CTP） - 抗原复合物脉冲化PBMC，单核细胞或B细胞来制备靶细胞; 用效应细胞处理靶细胞; 并分析靶细胞的裂解。此外，还提供了用于测量细胞毒性T淋巴细胞活性的试剂盒。

3. 发明授权

US06780618B2 Method for improving genetic stability of foreign insert nucleotide sequence in recombinant poliovirus 失效
标题翻译：改善重组脊髓灰质炎病毒外源插入核苷酸序列遗传稳定性的方法
公开(公告)号：US06780618B2
公开(公告)日：2004-08-24
申请号：US10071867
申请日：2002-02-08
申请人： Sang-Gu Lee , Dae-You Kim , Ki-Tae Kim , Yong-Soo Bae
发明人： Sang-Gu Lee , Dae-You Kim , Ki-Tae Kim , Yong-Soo Bae
IPC分类号： C12N1568
CPC分类号： C12N15/64 , C12N15/86 , C12N2770/32643 , C12Q1/702
摘要： The present invention relates to (a) methods for improving a genetic stability of an insert nucleotide sequence in a recombinant single-stranded RNA virus vector, which comprises performing a mutagenesis of the foreign insert nucleotide sequence to provide even distribution of G/C content throughout the overall foreign insert nucleotide sequence and/or to increase G/C content of the foreign insert without substantially causing amino acids substitutions (b) a recombinant single-stranded RNA virus comprising an insert nucleotide sequence with improved genetic stability and (c) a recombinant poliovirus comprising an insert nucleotide sequence with improved genetic stability.
摘要翻译：本发明涉及（a）用于提高重组单链RNA病毒载体中插入核苷酸序列的遗传稳定性的方法，其包括进行外源插入核苷酸序列的诱变以提供G / C含量的均匀分布总体外源插入核苷酸序列和/或增加外源插入物的G / C含量而基本上不引起氨基酸取代（b）包含具有改善的遗传稳定性的插入核苷酸序列的重组单链RNA病毒，和（c）重组包含具有改善遗传稳定性的插入核苷酸序列的脊髓灰质炎病毒。

4. 发明申请

US20100215624A1 Pharmaceutical Compositions for Treating Rheumatoid Arthritis Comprising Semi-Mature Dendritic Cell 审中-公开
标题翻译：用于治疗包含半成熟树突状细胞的类风湿关节炎的药物组合物
公开(公告)号：US20100215624A1
公开(公告)日：2010-08-26
申请号：US12597259
申请日：2008-03-12
申请人： Mi-Sun Kang , Dae-Seog Lim , Ju-Ah Jeong , Hyun-Soo Lee , Yong-Soo Bae
发明人： Mi-Sun Kang , Dae-Seog Lim , Ju-Ah Jeong , Hyun-Soo Lee , Yong-Soo Bae
IPC分类号： A61K35/30 , C12N5/0784 , A61P29/00 , A61P19/00
CPC分类号： A61K39/0008 , A61K2035/122 , A61K2039/5154 , C12N5/064 , C12N2501/22 , C12N2501/25
摘要： The present invention relates to a pharmaceutical composition for treating rheumatoid arthritis, which comprises (a) a pharmaceutically effective amount of a semi-mature dendritic cell; and (b) a pharmaceutically acceptable carrier. The semi-mature dendritic cell of this invention has a safe and remarkably improved potential to treat or prevent rheumatoid arthritis through the activity of the suppression of auto-immune responses.
摘要翻译：本发明涉及一种用于治疗类风湿性关节炎的药物组合物，其包含（a）药学有效量的半成熟树突状细胞; 和（b）药学上可接受的载体。本发明的半成熟树突状细胞通过抑制自身免疫应答的活性具有安全和显着改善的治疗或预防类风湿性关节炎的潜力。

5. 发明授权

US07101844B2 Cytoplasmic transduction peptides and uses thereof 有权
标题翻译：细胞质转导肽及其用途
公开(公告)号：US07101844B2
公开(公告)日：2006-09-05
申请号：US10509620
申请日：2003-03-28
申请人： Dae-You Kim , Hae-Keun Oh , Chang-Hyun Kim , Jung-Hwan Kim , Choon-Ju Jeon , Ki-Tae Kim , Yong-Soo Bae , In-Soo Choi
发明人： Dae-You Kim , Hae-Keun Oh , Chang-Hyun Kim , Jung-Hwan Kim , Choon-Ju Jeon , Ki-Tae Kim , Yong-Soo Bae , In-Soo Choi
IPC分类号： A01N37/18
摘要： The present invention relates to a cytoplasmic transduction peptide (CTP) showing transduction potential, as well as cytoplasmic remaining potential and various uses thereof. The CTP of this invention exhibits a transduction potential identical or higher than the conventional protein transduction, PTD, and a strong tendency to remain in the cytoplasm, so that it is very useful in inducing cytotoxic T lymphocytes (CTL) and a drug delivery system (DDS) targeting cytoplasm.
摘要翻译：本发明涉及显示转导电位的细胞质转导肽（CTP），以及细胞质剩余电位及其各种用途。本发明的CTP显示出与常规蛋白转导（PTD）相同或更高的转导电位，并且具有保留在细胞质中的强烈倾向，因此其在诱导细胞毒性T淋巴细胞（CTL）和药物递送系统 DDS）靶向细胞质。

6. 发明申请

US20050142555A1 Novel dendritic cell-specific polynucleotides and microarray comprising the same 审中-公开
标题翻译：新型树突细胞特异性多核苷酸和包含其的微阵列
公开(公告)号：US20050142555A1
公开(公告)日：2005-06-30
申请号：US10509621
申请日：2003-03-28
申请人： Jung-Hoon Anh , Yoon Lee , Choon-ju Jeon , Byung-Hak Lee , Kang-Duk Choi , Yong-Soo Bae
发明人： Jung-Hoon Anh , Yoon Lee , Choon-ju Jeon , Byung-Hak Lee , Kang-Duk Choi , Yong-Soo Bae
IPC分类号： C07H21/00 , C12Q1/68 , C07H21/04 , C12M1/34
CPC分类号： C07H21/00
摘要： The present invention relates to dentritic cell-specific polynucleotides and microarrays, particularly to novel polynucleotides highly expressed in dendritic cells, certain dendritic cell subsets and matured dendritic cells and microarrays comprising thereof. With a marrcoarray of this invention, dendritic cells, certain dendritic cells subsets and matured dendritic cells can be detected rapidly and accurately.
摘要翻译：本发明涉及树突细胞特异性多核苷酸和微阵列，特别涉及在树突细胞中高度表达的新型多核苷酸，某些树突状细胞亚群和成熟树突状细胞以及包含其的微阵列。利用本发明的糖浆体，可以快速，准确地检测树突状细胞，某些树状细胞亚群和成熟的树突状细胞。

7. 发明授权

US06696289B1 Replication-competent recombinant Sabin type 1 strain of poliovirus 失效
标题翻译：具有复制能力的重组Sabin 1型脊髓灰质炎病毒株
公开(公告)号：US06696289B1
公开(公告)日：2004-02-24
申请号：US09284349
申请日：1999-06-04
申请人： Yong Soo Bae , Hye Rhan Jung
发明人： Yong Soo Bae , Hye Rhan Jung
IPC分类号： C12N1574
CPC分类号： C07K14/005 , A61K39/00 , C12N15/86 , C12N2740/16122 , C12N2740/16222 , C12N2770/32643 , Y02A50/466
摘要： A replication-competent recombinant Sabin type 1 poliovirus vector containing a sequence coding for multiple cloning site and 3C-protease cleavage site is provided. This vector makes it easy to introduce various vaccine genes from infectious viruses to the Sabin 1 poliovirus, and facilitates to produce chimeric Sabin 1 polioviruses that are expected to be powerful oral mucosal vaccines against several infectious viral diseases.
摘要翻译：提供了含有编码多克隆位点和3C-蛋白酶切割位点的序列的具有复制能力的重组Sabin 1型脊髓灰质炎病毒载体。该载体使得易于将各种疫苗基因从感染性病毒引入Sabin 1脊髓灰质炎病毒，并且有助于产生预期是针对几种感染性病毒性疾病的强力口腔粘膜疫苗的嵌合Sabin 1脊髓灰质炎病毒。

8. 发明授权

US08623348B2 Interferon-α (IFN-α) fused proteins comprising IFN-α and a cytoplasmic transduction peptide (CTP) 有权
标题翻译：包含IFN-α和细胞质转导肽（CTP）的干扰素-α（IFN-α）融合蛋白
公开(公告)号：US08623348B2
公开(公告)日：2014-01-07
申请号：US13260490
申请日：2009-03-27
申请人： Chan Kyu Lee , Seonyoung Yang , Eun Ju Kang , Kang Ryu , Hyun Soo Lee , Yong Soo Bae
发明人： Chan Kyu Lee , Seonyoung Yang , Eun Ju Kang , Kang Ryu , Hyun Soo Lee , Yong Soo Bae
IPC分类号： A61K38/21 , A61K39/00 , A61K39/385 , C07K14/56 , C12P21/04
CPC分类号： C07K14/56 , A61K38/00 , C07K2319/00 , C07K2319/10
摘要： Disclosed is an interferon-α (IFN-α) fused protein having IFN-α fused to a cytoplasmic transduction peptide (CTP). The disclosure relates to a fused protein wherein a CTP, which binds well to cell-membrane barriers and enables translocation into the liver, is genetically fused to a human IFN-α, thereby enhancing the conjugation capacity of cell membranes and antiviral activity, inhibiting CTP transport into the cell nucleus, and enhancing the translocation and settlement of the fused protein into the liver and of transduction to the liver tissue. Accordingly, it is possible to develop protein-based medicines effective for preventing or treating various liver diseases associated with viral infection at low doses.
摘要翻译：公开了具有与细胞质转导肽（CTP）融合的IFN-α的干扰素-α（IFN-α）融合蛋白。本公开涉及融合蛋白，其中与细胞膜屏障良好结合并能够转运到肝脏中的CTP与人IFN-α遗传融合，从而增强细胞膜的共轭能力和抗病毒活性，抑制CTP 运输到细胞核，并增强融合蛋白的转运和沉降进入肝脏和向肝组织转导。因此，可以开发有效预防或治疗与低剂量病毒感染相关的各种肝脏疾病的蛋白质类药物。

9. 发明申请

US20120134961A1 Interferon-alpha (IFN-alpha) Fused Protein Having IFN-alpha and Cytoplasmic Transduction Peptide (CTP) 有权
标题翻译：具有IFN-α和细胞质转导肽（CTP）的干扰素-α（IFN-α）融合蛋白
公开(公告)号：US20120134961A1
公开(公告)日：2012-05-31
申请号：US13260490
申请日：2009-03-27
申请人： Chan Kyu Lee , Seonyoung Yang , Ju Kang , Kang Ryu , Hyun Soo Lee , Yong Soo Bae
发明人： Chan Kyu Lee , Seonyoung Yang , Ju Kang , Kang Ryu , Hyun Soo Lee , Yong Soo Bae
IPC分类号： A61K38/21 , C12N15/21 , C12N15/63 , A61P35/00 , C12N1/19 , C12N5/10 , C12P21/00 , A61P1/16 , C07K14/56 , C12N1/21
CPC分类号： C07K14/56 , A61K38/00 , C07K2319/00 , C07K2319/10
摘要： Disclosed is an interferon-α (IFN-α) fused protein having IFN-α fused to a cytoplasmic transduction peptide (CTP). The disclosure relates to a fused protein wherein a CTP, which binds well to cell-membrane barriers and enables translocation into the liver, is genetically fused to a human IFN-α, thereby enhancing the conjugation capacity of cell membranes and antiviral activity, inhibiting CTP transport into the cell nucleus, and enhancing the translocation and settlement of the fused protein into the liver and of transduction to the liver tissue. Accordingly, it is possible to develop protein-based medicines effective for preventing or treating various liver diseases associated with viral infection at low doses.
摘要翻译：公开了具有与细胞质转导肽（CTP）融合的IFN-α的干扰素-α（IFN-α）融合蛋白。本公开涉及融合蛋白，其中与细胞膜屏障良好结合并能够转运到肝脏中的CTP与人IFN-α遗传融合，从而增强细胞膜的共轭能力和抗病毒活性，抑制CTP 运输到细胞核，并增强融合蛋白的转运和沉降进入肝脏和向肝组织转导。因此，可以开发有效预防或治疗与低剂量病毒感染相关的各种肝脏疾病的蛋白质类药物。

10. 发明申请

US20050154188A1 Cytoplasmic tranduction peptides and uses thereof 有权
标题翻译：细胞质转导肽及其用途
公开(公告)号：US20050154188A1
公开(公告)日：2005-07-14
申请号：US10509620
申请日：2003-03-28
申请人： Dae-You Kim , Hae-Keun Oh , Chang-Hyun Kim , Jung-Hwan Kim , Choon-Ju Jeon , Yong-Soo Bae , In-Soo Choi
发明人： Dae-You Kim , Hae-Keun Oh , Chang-Hyun Kim , Jung-Hwan Kim , Choon-Ju Jeon , Yong-Soo Bae , In-Soo Choi
IPC分类号： A61K38/00 , C07K7/06 , C07K14/705
摘要： The present invention relates to a cytoplasmic transduction peptide (CTP) showing transduction potential, as well as cytoplasmic remaining potential and various uses thereof. The CTP of this invention exhibits a transduction potential identical or higher than the conventional protein transduction, PTD, and a strong tendency to remain in the cytoplasm, so that it is very useful in inducing cytotoxic T lymphocytes (CTL) and a drug delivery system (DDS) targeting cytoplasm.
摘要翻译：本发明涉及显示转导电位的细胞质转导肽（CTP），以及细胞质剩余电位及其各种用途。本发明的CTP显示出与常规蛋白转导（PTD）相同或更高的转导电位，并且具有保留在细胞质中的强烈倾向，因此其在诱导细胞毒性T淋巴细胞（CTL）和药物递送系统 DDS）靶向细胞质。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式